| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Withdrawn | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repai NCT06527690 | Latin American Cooperative Oncology Group | Phase 2 |
| Unknown | Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Sta NCT05627752 | Zhongnan Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease NCT05570994 | British Columbia Cancer Agency | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer NCT05766371 | University of California, San Francisco | Phase 2 |
| Withdrawn | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients NCT05156372 | The University of Texas Health Science Center at San Antonio | N/A |
| Recruiting | TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid NCT04969315 | Portage Biotech | Phase 1 / Phase 2 |
| Withdrawn | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cance NCT05582031 | Translational Research in Oncology | Phase 2 |
| Recruiting | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer NCT06783127 | Santa Chiara Hospital | — |
| Recruiting | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies NCT05488548 | Epigenetix, Inc. | Phase 1 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas NCT05415098 | Ascentage Pharma Group Inc. | Phase 1 |
| Withdrawn | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NCT05191017 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Completed | A Study of PRT2527 in Participants With Advanced Solid Tumors NCT05159518 | Prelude Therapeutics | Phase 1 |
| Completed | PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer NCT04768608 | Zhejiang University | Phase 1 |
| Active Not Recruiting | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide NCT04335682 | Alliance Foundation Trials, LLC. | Phase 2 |
| Terminated | Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Canc NCT04737109 | David VanderWeele | Phase 1 / Phase 2 |
| Active Not Recruiting | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA NCT04319783 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Withdrawn | Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progres NCT04296578 | Stanford University | Phase 1 |
| Suspended | LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer NCT04053062 | Bioray Laboratories | Phase 1 |
| Completed | Checkpoint Inhibitors and SBRT for MCRPC NCT05655715 | Herlev and Gentofte Hospital | Phase 2 |
| Completed | Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Ra NCT04995614 | Radboud University Medical Center | — |
| Completed | Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastati NCT02814669 | Hoffmann-La Roche | Phase 1 |
| Completed | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal NCT02259114 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer NCT01832870 | Prostate Oncology Specialists, Inc. | Phase 1 |
| Terminated | A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Ca NCT01717898 | Charles Ryan | Phase 1 / Phase 2 |
| Terminated | A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over T NCT01907009 | Barts & The London NHS Trust | Phase 2 / Phase 3 |
| Completed | Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostat NCT01599793 | University of Chicago | Phase 2 |
| Terminated | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naiv NCT01313559 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients NCT01352208 | Astellas Pharma Inc | Phase 1 / Phase 2 |
| Completed | Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer NCT01824342 | Amgen | Phase 3 |
| Completed | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) NCT01234025 | Ionis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy NCT01144897 | Daniel Vaena | Phase 1 |
| Terminated | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as NCT01083615 | Achieve Life Sciences | Phase 3 |
| Completed | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prosta NCT00838201 | Amgen | Phase 3 |
| Completed | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant NCT00770848 | Amgen | Phase 1 / Phase 2 |